Dublin, 21 July 2020 (GLOBE NEWSWIRE) – Evaluation of market opportunities for the diagnosis of COVID-19 (PCR tests, antibody tests) and treatments (immunotherapy, vaccines, antivirals, cell-based, plasma therapy) and global forecasts up to 2025″ report has been added to the ResearchAndMarkets.com offering. Health systems are suffering to manage the global population of COVID-19 patients and, as a result, medical scholars are rushing to find a solution to the pandemic. According to the latest publication, key spaces in studies include antibodies, protein-based vaccines, antivirals, drug reuse, RNA-based vaccines, non-replicative viral vectors, and cell-based treatments. While more than 50% of progression treatments are in the preclinical stage, government initiatives, such as the FDA’s Emergency Use Authorization (USA), are expected to drive studies and the progression process.
Based on the characteristics of fitness care, the effect on COVID-19 evaluation on diagnostic and remedy domains is analyzed. It is estimated that the market opportunity for these products will succeed at USD 13.9 billion in 2025. The diagnostic segment is further divided into PCR-based tests and antibody tests. The mastery of the remedy is segmented into vaccines, immunotreated, antiviral, mobile treatments and other treatments. Vaccines and antivirals are the characteristics of the most explored remedies that are being studied lately through researchers around the world. Geographically, North America was the worst-affected region, basically because the United States is the worst hit country with the highest number of cases shown and deaths in the world. Other top countries affected are the United Kingdom, Spain, France, Italy, Brazil, Germany and India, among others. In addition, at most all affected countries experienced an immediate economic decline, resulting in a decline in GDP, emerging unemployment rates and emerging inflation rates.
To succeed on the situation, governments have imposed restrictions on other people’s movements and invested resources to deal with the crisis and help all medical studies and efforts to expand a remedy option. The United States, Canada, the United Kingdom, Germany, China and India are some of the leading countries leading studies and production efforts aimed at the progression of COVID-19 medicines. Some of the key players involved in the diagnosis and progression of COVID-19 remedies are Roche Holding AG (Switzerland), Thermo Fisher Scientific, Inc. (USA), Abbott Laboratories (USA), Becton, Dickinson and Company (USA), AbbVie Corporation (USA), Gilead Sciences, Inc. (USA), Eli Lilly and Company (USA), Moderna, Inc. (USA), Novavax, Inc. (USA), , Inc. (USA), Inovio Pharmaceuticals, Inc. (USA), GlaxoSmithKline (United Kingdom), Sanofi LTD Johnson and Johnson (USA), Sorrento Therapeutics, Inc. (USA), AstraZen Plceca (UNITED Kingdom), Pfizer, Inc. (USA), CTI Biopharma Corporation (USA) , OncoImmune, Inc. (USA), Athersys, Inc. (USA), Celularity, Inc. (USA), Pluristem Therapeutics (Israel) and Takeda Pharmaceuticals Company Ltd (Japan), among others.
Key topics covered:
Companies mentioned
For more information on this report, https://www.researchandmarkets.com/r/cvgzn9
Reseek and Markets also offers custom searches that offer a targeted, complete and personalized search.